DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 STUDY EVALUATING EFFICACY AND SAFETY OF IGPRO20 (SUBCUTANEOUS IMMUNOGLOBULIN, HIZENTRA®) IN POST COVID-19 POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME (POTS)

Registry ID

IGPRO20_3010

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

CSL BEHRING

Last update

2024-07-17

Conditions

• POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME

Related clinical trials

• A PHASE 2 DOUBLE-BLIND PLACEBO-CONTROLLED SINGLE-DOSE STUDY OF PHARMACODYNAMICS, PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF REGN7544, AN NPR1 ANTAGONIST MONOCLONAL ANTIBODY, IN PATIENTS WITH POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME

View on source registry